Provided by Tiger Trade Technology Pte. Ltd.

VanEck Pharmaceutical ETF

109.44
-0.1600-0.15%
Post-market: 109.440.00000.00%19:30 EDT
Volume:128.97K
Turnover:14.12M
Market Cap:1.01B
PE:88.68
High:110.48
Open:110.00
Low:109.17
Close:109.60
52wk High:118.00
52wk Low:85.91
Shares:9.19M
Float Shares:9.19M
Volume Ratio:0.66
T/O Rate:1.40%
Dividend:2.17
Dividend Rate:1.98%
EPS(TTM):1.23
EPS(LYR):0.7765
ROE:--
ROA:--
PB:--
PE(LYR):140.94

Loading ...

Analysts Conflicted on These Healthcare Names: Moderna (MRNA), Merck & Company (MRK) and Pacific Biosciences (PACB)

TIPRANKS
·
Sep 11

Novartis Needs to Make Progress on Pipeline to Justify Valuation

Dow Jones
·
Sep 11

Morgan Stanley downgrades Novo Nordisk (0QIU) to a Sell

TIPRANKS
·
Sep 11

MS Cuts Novo Nordisk on Growth Prospects, Patent Expiry Risks

Reuters
·
Sep 11

Growth Without AI: 8 Stock Picks

Dow Jones
·
Sep 11

AbbVie Inc. Stock Outperforms Competitors on Strong Trading Day

Dow Jones
·
Sep 11

Insight Guru Flags Valuation Flip as Merck Trades at 52.2x Operating Profit vs Lilly 25.3x

Reuters
·
Sep 11

AbbVie Declares Quarterly Cash Dividend of $1.73 a Share

Reuters
·
Sep 11

Abbvie - Declares Qtrly Cash Dividend of $1.73 Per Share

THOMSON REUTERS
·
Sep 11

Novo Nordisk’s CagriSema Trial Targets Painful Diabetic Nerve Damage

TIPRANKS
·
Sep 11

AbbVie’s Eye Implant Study Delivers Fresh Real‑World Clarity for Investors

TIPRANKS
·
Sep 11

Eli Lilly is Maintained at Reduce by HSBC

Dow Jones
·
Sep 10

Eli Lilly’s GLP-1 Windfall to Fund Push into Women’s Health - Bloomberg News

Reuters
·
Sep 10

Novartis shareholder calls for board changes, Reuters reports

TIPRANKS
·
Sep 10

AbbVie Says Atogepant Met Primary, Secondary Endpoints in Phase 3 Menstrual Migraine Study

MT Newswires Live
·
Sep 10

AbbVie’s atogepant shows positive Phase 3 results in menstrual migraine

TIPRANKS
·
Sep 10

Abbvie - Atogepant Safety Results Consistent with Known Profile; no New Safety Signals

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Meets Primary and All Eight Ranked Secondary Endpoints in Phase 3 Luna Study

THOMSON REUTERS
·
Sep 10

Abbvie Extends Migraine Leadership with Positive Phase 3 Atogepant Results in Menstrual Migraine

THOMSON REUTERS
·
Sep 10

Abbvie - Atogepant Shows Significant Improvements Across Multiple Endpoints Versus Placebo

THOMSON REUTERS
·
Sep 10